← back to search

Vanessa Stadlbauer

Medical University of Vienna · AT
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment, Gut microbiota and health, and Organ Transplantation Techniques and Outcomes.
h-index
50
citations
9,220
works
377
NIH funding
primary concept
Medicine
email

Recent publications

An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study
Clinical Nutrition 2026cited by 1position: contributordoi
The beneficial effect of a multispecies probiotic intervention on quality of sleep - a randomized, double-blinded, placebo-controlled study.
2026cited by 0position: contributordoi
Prognostic Value of Exercise Testing in Patients with Liver Cirrhosis.
2026cited by 0position: contributordoi
Microbial Dysbiosis in the Urinary Microbiome of Patients With Cirrhosis.
2026cited by 0position: contributordoi
Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort study.
2026cited by 0position: contributordoi
MyBioScope: a new frontier in gut microbiome and health research
Bioresources and Bioprocessing 2026cited by 0position: contributordoi
Surgery and the Gastrointestinal Microbiome in Cancer: Bidirectional Impacts and Therapeutic Opportunities – a Narrative Review
Surgical Oncology 2026cited by 0position: contributordoi
The microplastic-crisis: Role of bacteria in fighting microplastic-effects in the digestive system.
2025cited by 10position: contributordoi
Depletion of Small HDL Subclasses Predicts Poor Survival in Liver Cirrhosis.
2025cited by 0position: contributordoi
Human gut microbiome: Therapeutic opportunities for metabolic syndrome-Hype or hope?
2024cited by 15position: contributordoi
Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study.
2024cited by 6position: contributordoi
Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study.
2024cited by 3position: contributordoi
Gut Microbiome Changes After Neoadjuvant Chemotherapy and Surgery in Patients with Gastric Cancer.
2024cited by 3position: contributordoi
Cellular and Microbial In Vitro Modelling of Gastrointestinal Cancer.
2024cited by 1position: contributordoi
Effect of albumin infusion on oxidative albumin modification and albumin binding capacity in chronic liver failure.
2024cited by 1position: contributordoi
Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis.
2023cited by 33position: contributordoi
Fungal translocation measured by serum 1,3-ß-D-glucan correlates with severity and outcome of liver cirrhosis-A pilot study.
2023cited by 12position: contributordoi
Circulating neutrophil anti-pathogen dysfunction in cirrhosis.
2023cited by 9position: contributordoi
Probiotic OMNi-BiOTiC<sup>®</sup> 10 AAD Reduces Cyclophosphamide-Induced Inflammation and Adipose Tissue Wasting in Mice.
2023cited by 6position: contributordoi
Liver-Gut-Interaction: Role of Microbiome Transplantation in the Future Treatment of Metabolic Disease.
2023cited by 4position: contributordoi
Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?
2023cited by 4position: contributordoi
Serum bile acids in liver cirrhosis promote neutrophil dysfunction.
2022cited by 16position: contributordoi
Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators.
2022cited by 12position: contributordoi
A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS - Modified TIPS Score.
2022cited by 11position: contributordoi
Insights into the Composition of a Co-Culture of 10 Probiotic Strains (OMNi BiOTiC<sup>®</sup> AAD10) and Effects of Its Postbiotic Culture Supernatant.
2022cited by 9position: contributordoi
Pulmonary vascular disease and exercise hemodynamics in chronic liver disease.
2022cited by 6position: contributordoi
Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis.
2022cited by 6position: contributordoi
Red urine and a red herring - diagnosing rare diseases in the light of the COVID-19 pandemic.
2022cited by 4position: contributordoi
The Pre-Analytical CEN/TS Standard for Microbiome Diagnostics-How Can Research and Development Benefit?
2022cited by 4position: contributordoi
Criminal and Civil Responsibility of the Donor in a Case of Transmission of Malaria by a Blood Transfusion in a Nonendemic Country.
2022cited by 2position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 54 papers (2019–2026)Angela Horvath · University of California, San Diego17 papers (2019–2026)Florian Rainer · Medical University of Graz6 papers (2020–2024)Rudolf Stauber · University of Amsterdam5 papers (2020–2026)Tobias Madl · Graz University of Technology5 papers (2019–2025)Frank Lammert · Medical University of Warsaw4 papers (2014–2017)Marcin Krawczyk · Medical University of Warsaw3 papers (2016–2017) · 3 papers (2016–2017) · 3 papers (2016–2017)Peter Fickert · Ludwig-Maximilians-Universität München3 papers (2016–2017) · 3 papers (2016–2017)Hansjörg Habisch · Universität Ulm3 papers (2024–2025)Patricia Fuchs · University of Bern3 papers (2021–2023)Christoph Castellani · Medical University of Graz3 papers (2021–2023)Vasile Foris · Ludwig Boltzmann Institute for Digital Health and Prevention3 papers (2022–2026)Wolfram Miekisch · University of Rostock3 papers (2021–2023)Irina Balazs · Center For Biomarker Research In Medicine3 papers (2022–2024) · 3 papers (2021–2023)Torsten Voigtländer · Medizinische Hochschule Hannover3 papers (2016–2017)Gabriele Kirchner · University of Regensburg3 papers (2016–2017)